EUVIMEDEUVIMED entdecken
Crossref

Deciphering the neuroprotective signaling of SGLT2 inhibitors in Alzheimer's disease

Takahiro Kamihara iD, Ryutah Kato, Akira Morisaki, Shinji Kaneko, Takuya Omura iD, Atsuya Shimizu

Journal of Alzheimer’s Disease · 30.10.2026

DOI: 10.1177/13872877261502860 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Alzheimer’s Disease, online erschienen am 30.10.2026. Verfasst von Takahiro Kamihara und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, National Center for Geriatrics and Gerontology, Obu, Japan. Die Arbeit nennt 42 Literaturangaben. Gefördert von: The grants from the Research Funding of Longevity Sciences from the National Center for Geriatrics and Gerontology, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Alzheimer's disease (AD) currently lacks fundamental curative treatments. While epidemiological evidence increasingly links sodium-glucose cotransporter 2 (SGLT2) inhibitors to reduced AD risk, the underlying molecular mechanisms remain poorly understood.

Objective

This study aimed to elucidate the potential molecular pathways through which SGLT2 inhibitors intervene in AD pathophysiology using a bioinformatics approach.

Methods

Potential targets for empagliflozin and dapagliflozin were predicted via SwissTargetPrediction. AD-related differentially expressed genes (DEGs) were identified from a human brain dataset (GSE125583) utilizing the GREIN platform. Common genes were analyzed for functional networks (GeneMANIA/STRING) and pathway enrichment (KEGG). Hub proteins were identified using Cytoscape centrality metrics, and organ-specific expression was verified through the RefEx database.

Results

Fifty-seven genes were common to SGLT2 inhibitor targets and AD DEGs. Notably, the transporters SLC5A11 and SLC2A1 were significantly upregulated in AD brains and exhibited high brain-specific expression. Pathway analysis revealed significant involvement in the MAPK and FoxO signaling pathways, which regulate apoptosis, autophagy, and oxidative stress. Key hub proteins identified included ERBB2, HSP90AA1, DPP4, and SLC2A1. It is hypothesized that SGLT2 inhibitors exert neuroprotective effects by targeting these upregulated transporters, thereby suppressing MAPK signaling and activating the FoxO pathway.

Conclusions

Our findings suggest that SGLT2 inhibitors may normalize MAPK/FoxO signaling and restore cellular homeostasis in the AD brain. This study provides a potential theoretical insight for the drug repositioning of antidiabetic agents and offers key indicators for the design of future clinical and basic research in AD therapy.

Schlagwörter

Stichwörter der Autor:innen

Alzheimer's diseaseFoxO signalingSGLT2 inhibitorsbioinformaticsmechanism

Autor:innen und Institutionen

  • Department of Cardiology, National Center for Geriatrics and Gerontology, Obu, Japan.
  • Graduate School of International Social Sciences, Yokohama National University, Yokohama, Japan.
  • Support and Research Center, Tokyo Gakugei University, Tokyo, Japan.
  • Department of Cardiology, Toyota Kosei Hospital, Toyota, Japan.
  • Department of Metabolic Research, National Center for Geriatrics and Gerontology, Obu, Japan.

ORCID-Profile: Takahiro Kamihara, Takuya Omura

Förderung

  • The grants from the Research Funding of Longevity Sciences from the National Center for Geriatrics and Gerontology
  • Japan Society for the Promotion of Science

Zitieren

APA

Kamihara, T., Kato, R., Morisaki, A., Kaneko, S., Omura, T., & Shimizu, A. (2026). Deciphering the neuroprotective signaling of SGLT2 inhibitors in Alzheimer's disease. Journal of Alzheimer’s Disease. https://doi.org/10.1177/13872877261502860

Vancouver

Kamihara T, Kato R, Morisaki A, Kaneko S, Omura T, Shimizu A. Deciphering the neuroprotective signaling of SGLT2 inhibitors in Alzheimer's disease. Journal of Alzheimer’s Disease. 2026. doi:10.1177/13872877261502860

BibTeX
@article{Kamihara2026,
  author = {Kamihara, Takahiro and Kato, Ryutah and Morisaki, Akira and Kaneko, Shinji and Omura, Takuya and Shimizu, Atsuya},
  title = {Deciphering the neuroprotective signaling of SGLT2 inhibitors in Alzheimer's disease},
  journal = {Journal of Alzheimer’s Disease},
  year = {2026},
  doi = {10.1177/13872877261502860}
}
Kostenlos starten →